Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

1Total
P 1 (1)

Trial Status

Completed2
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04183218Completed

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

NCT04391049Phase 1Active Not Recruiting

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

NCT04501913Completed

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes

Showing all 3 trials

Research Network

Activity Timeline